Key Points
- Werewolf director Luke Evnin sold 79,086 shares on May 7 at an average price of $0.63 for $49,824, leaving him with 1,578,749 shares (a 4.77% reduction); the sale was disclosed in an SEC filing and executed under a pre-arranged Rule 10b5-1 plan.
- Across April 27–May 7 Evnin sold a total of 581,111 shares in multiple transactions, including large blocks on April 30 (168,262 shares) and April 28 (95,412 shares), all under the same trading plan.
- Stock context: HOWL shares traded around $0.62 with a market cap of about $30.1M and a 52-week range of $0.53–$2.38; analysts hold a consensus "Hold" with a $3.75 target and the company recently beat quarterly EPS estimates (‑$0.28 vs. ‑$0.32).
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18. Following the transaction, the director owned 1,578,749 shares in the company, valued at $994,611.87. This represents a 4.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
- On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
- On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
- On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
- On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $121,148.64.
- On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $39,025.71.
- On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.
- On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total transaction of $45,849.00.
Werewolf Therapeutics Stock Performance
Shares of NASDAQ:HOWL opened at $0.62 on Friday. The firm has a market cap of $30.13 million, a price-to-earnings ratio of -0.46 and a beta of 0.41. The firm has a fifty day moving average price of $0.81 and a 200 day moving average price of $0.85. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04. As a group, research analysts predict that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.
Wall Street Analysts Forecast Growth
HOWL has been the topic of a number of research analyst reports. Wall Street Zen upgraded Werewolf Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, April 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $3.75.
Check Out Our Latest Stock Analysis on Werewolf Therapeutics
Hedge Funds Weigh In On Werewolf Therapeutics
Several hedge funds have recently bought and sold shares of HOWL. Regal Investment Advisors LLC increased its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company's stock worth $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company's stock valued at $38,000 after purchasing an additional 24,003 shares during the period. Renaissance Technologies LLC grew its stake in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Susquehanna International Group LLP grew its stake in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics during the 3rd quarter worth $304,000. Institutional investors own 64.84% of the company's stock.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
